Anti-CD29 [12G10]

Absolute Antibody

Anti-CD29 [12G10]

9

This antibody recognises a ligand-induced binding site on the betaA domain of beta1 integrin, and thus reacts preferentially with alpha5beta1 integrins in the ligand-activated state. Binding of this antibody alters the position of the alpha1 helix of beta

This antibody reacts with beta1 integrins in Western blotting (Mould et al, 1995). ELISA analysis has revealed the ability of this antibody to enhance the interaction between beta1 integrin and its ligand, fibronectin (Mould et al, 1995). Indeed, activation of integrins by this antibody reduced the induction of osteosarcoma growth and inhibition of NF-kappaB caused by hERG1 knockdown in osteosarcoma cells (Zeng et al, 2016). This antibody has been used to specifically label ligand-bound cell surface beta1 integrins both in immunohistochemical analysis (Izumi et al, 2015; Chao & Kunz, 2009), including in situ proximity ligation (PLA) analysis (Nevo et al, 2010), and in FACS analysis (Brandt et al, 2009).

Flow Cytometry, Western Blot, ELISA, ImmunoHistoChemistry, Other Application

Research Use Only

Monoclonal

12G10

ITGB1

integrin subunit beta 1

CD29; FNRB; glycoprotein IIa; GPIIA; integrin beta 1; integrin beta-1; integrin VLA-4 beta subunit; integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12); MDF2; MSK12; very late activation protein, beta polypeptide; VLAB; VLA-BETA

Human

IgG4

Integrin beta-1

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203